Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial.

Quality of life determined by DLQI was ameliorated in both the omiganan (−2.6, 95% CI −6.4 to −1.1, p = 0.1671) and ketoconazole (−2.1, 95% CI −5.8 to −1.7, p = 0.2811) treatment groups compared to the placebo at EOT but did not reach statistical significance ( Figure 1 d).

also in 111,027 other papers